amrinone has been researched along with Cardiomyopathies in 4 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study compared the effects of amrinone, dobutamine, dibutyryl cAMP, digoxin, and isoproterenol on mechanical performance, the high energy phosphate metabolites, and the [Ca2+]i transients in normal and cardiomyopathic hamster hearts with severe heart failure." | 3.69 | Distinct modulation of myocardial performance, energy metabolism, and [Ca2+]i transients by positive inotropic drugs in normal and severely failing hamster hearts. ( Buser, PT; Jasmin, G; Parmley, WW; Wikman-Coffelt, J; Wu, SY, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buser, PT | 2 |
| Wu, SY | 1 |
| Parmley, WW | 2 |
| Jasmin, G | 2 |
| Wikman-Coffelt, J | 2 |
| Matsui, S | 1 |
| Matsumori, A | 1 |
| Matoba, Y | 1 |
| Uchida, A | 1 |
| Sasayama, S | 1 |
| Lawless, ST | 1 |
| Zaritsky, A | 1 |
| Miles, M | 1 |
| Auffermann, W | 1 |
| Wu, ST | 1 |
4 other studies available for amrinone and Cardiomyopathies
| Article | Year |
|---|---|
Distinct modulation of myocardial performance, energy metabolism, and [Ca2+]i transients by positive inotropic drugs in normal and severely failing hamster hearts.
Topics: Amrinone; Animals; Blood Pressure; Bucladesine; Calcium; Cardiomyopathies; Cardiotonic Agents; Crice | 1995 |
Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
Topics: Amrinone; Animals; Cardiomyopathies; Cardiovirus Infections; Encephalomyocarditis virus; Female; Imm | 1994 |
The acute pharmacokinetics and pharmacodynamics of amrinone in pediatric patients.
Topics: Amrinone; Cardiomyopathies; Child, Preschool; Heart Diseases; Hemodynamics; Humans; Infant; Infant, | 1991 |
Dobutamine potentiates amrinone's beneficial effects in moderate but not in advanced heart failure. 31P-MRS in isolated hamster hearts.
Topics: Amrinone; Animals; Cardiac Output, Low; Cardiomyopathies; Cricetinae; Dobutamine; Drug Combinations; | 1990 |